Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial

Blood

Volumn 99, Issue 3, 2002, Pages 731-735

  Moreau, Philippe ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Facon, Thierry ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Attal, Michel ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Hulin, Cyrille ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Michallet, Mauricette ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Maloisel, Frédéric ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Sotto, Jean Jacques ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Guilhot, François ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Marit, Gérald ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Doyen, Chantal ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Jaubert, Jérôme ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Fuzibet, Jean Gabriel ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   François, Sylvie ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Benboubker, Lotfi ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Monconduit, Matthieu ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Voillat, Laurent ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Macro, Margaret ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Berthou, Christian ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Dorvaux, Véronique ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Pignon, Bernard ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Rio, Bernard ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Matthes, Thomas ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Casassus, Philippe ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Caillot, Denis ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Najman, Norbert ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Grosbois, Bernard ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Bataille, Régis ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x}   Harousseau, Jean Luc ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y}   more..

^a Service d'Hematologie   (France)

^b Service d'Hématologie Pédiatriquc   (France)

^c Service D'Hematologie IUC Toulouse Oncopole   (France)

^d Service d'Hematologie Biologique   (France)

^e Service d'Hématologie   (France)

^f Service d'Hématologie   (France)

^g HÔpital Michallon   (France)

^h Service d'Hématologie   (France)

ⁱ Service d'Hematologie   (France)

^j Service d'hématologie HÔpital Erasme   (Belgium)

^k Service d'Hématologie   (France)

^l Service d'Hématologie Clinique HÔpital Archet 1   (France)

^m Serv d'Hematologie de l'Enfant   (France)

ⁿ Service d'Hématologie   (France)

^o Services d'Hematologie Biologique   (France)

^p Service d'Hematologie   (France)

^q Service d'Hematologie   (France)

^r Service d'Hématologie   (France)

^s Service d'Hématologie   (France)

^t Service d'Hématologie   (France)

^u Service d'Hematologie   (France)

^v HUG   (Switzerland)

^w Service d'hématologie Clinique   (France)

^x Service d hématologie et   (France)

^y HÔTEL DIEU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN;

ADULT; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

EID: 0036464598     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.3.731     Document Type: Article

References (19)

1. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
2. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
3. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study
4. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma
5. Total therapy with tandem transplants for newly diagnosed multiple myeloma
6. EBMT registry results of autologous bone marrow and peripheral stem cell transplantation
7. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: A comparative study of efficacy and toxicity from the Spanish registry for transplantation in multiple myeloma
8. Single versus double transplantation in myeloma: A prospective randomized trial of the Intergroupe Francophone du Myélome
9. Stem-cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: A randomized controlled trial
10. Busulphan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
11. Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma
12. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of a phase II trial involving 63 patients
13. Comparison of 3 high-dose regimens with autologous peripheral blood stem cell transplantation for multiple myeloma: A single center experience in 261 patients
14. Haemopoiesis of transplanted patients with autologous marrows assessed by long-term marrow culture
15. Stromal damage as consequence of high-dose chemo/ radiotherapy in bone marrow transplant recipients
16. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: Differences between peripheral blood stem cells and bone marrow recipients
17. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment
18. Relapse of multiple myeloma after autologous transplantation: Survival after salvage therapy
19. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft